UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Placebo Response and Practice Effects in Schizophrenia Cognition Trials

JAMA psychiatry (Chicago, Ill.), 2017-08, Vol.74 (8), p.807

2017

Volltextzugriff (PDF)

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

The American journal of psychiatry, 2016-08, Vol.173 (8), p.827-835

2016

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers

Journal of clinical pharmacology, 2010-08, Vol.50 (8), p.941-950

2010

Volltextzugriff (PDF)

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Schizophrenia bulletin, 2014-11, Vol.40 (6), p.1433-1442

2014

Volltextzugriff (PDF)

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers

The journal of clinical psychiatry, 2018-05, Vol.79 (3)

2018

Volltextzugriff (PDF)

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin

Pain (Amsterdam), 2008-06, Vol.136 (3), p.419-431

2008

Volltextzugriff (PDF)

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia

Journal of Alzheimer's disease, 2014, Vol.42 (3), p.959

2014

Volltextzugriff (PDF)

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Schizophrenia bulletin, 2016-01, Vol.42 (1), p.19-33

2016

Volltextzugriff (PDF)

Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid

Journal of psychopharmacology (Oxford), 2011-06, Vol.25 (6), p.763-773

2011

Volltextzugriff (PDF)

The alpha 7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Neuropsychopharmacology (New York, N.Y.), 2016-11, Vol.41 (12), p.2893-2902

2016

Volltextzugriff (PDF)

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Neuropsychopharmacology (New York, N.Y.), 2016-11, Vol.41 (12), p.2893-2902

2016

Volltextzugriff (PDF)

Evaluation of the abuse potential of pagoclone, a partial GABAA agonist

Journal of clinical psychopharmacology, 2006-06, Vol.26 (3), p.268-273

2006

Volltextzugriff (PDF)

The [alpha]7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Neuropsychopharmacology (New York, N.Y.), 2016-11, Vol.41 (12), p.2893

2016

Volltextzugriff (PDF)

Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance

Neuropsychiatric disease and treatment, 2008-03, Vol.4 (1), p.277-282

Caveney, Angela

2008

Volltextzugriff (PDF)

Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children

Journal of clinical pharmacology, 2001-05, Vol.41 (5), p.507-514

2001

Volltextzugriff (PDF)

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

Schizophrenia research, 2017-12, Vol.190, p.172-179

2017

Volltextzugriff (PDF)

A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia

The journal of pain, 2008-09, Vol.9 (9), p.792-805

2008

Volltextzugriff (PDF)

The H3 antagonist ABT‐288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

British journal of clinical pharmacology, 2014-06, Vol.77 (6), p.965-974

2014

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT‐288, in healthy young adults and elderly volunteers

British journal of clinical pharmacology, 2013-05, Vol.75 (5), p.1299-1311

2013

Volltextzugriff (PDF)

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective a7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

The American journal of psychiatry, 2016-08, Vol.173 (8), p.827

2016

Volltextzugriff (PDF)

The H 3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers: ABT-288 in subjects with schizophrenia

British journal of clinical pharmacology, 2014-06, Vol.77 (6), p.965-974

2014

Volltextzugriff (PDF)

Exposure-Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

Journal of clinical pharmacology, 2009-11, Vol.49 (11), p.1297-1308

2009

Volltextzugriff (PDF)

Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR)

Pharmacology, biochemistry and behavior, 2017-07, Vol.158, p.22-31

2017

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of the histamine H 3 receptor antagonist, ABT ‐288, in healthy young adults and elderly volunteers

British journal of clinical pharmacology, 2013-05, Vol.75 (5), p.1299-1311

2013

Volltextzugriff (PDF)

A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1

Journal of Alzheimer's disease, 2014-09, Vol.42 (3), p.959-971

2014

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Englisch
(156)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(77)
Humans
(47)
Male
(47)
Animals
(40)
Female
(38)
Biological And Medical Sciences
(30)
Adult
(19)
Cattle
(18)
Medical Sciences
(18)
Middle Aged
(14)
Fundamental And Applied Biological Sciences. Psychology
(13)
Genetics & Heredity
(12)
Malignant Catarrhal Fever
(12)
Sperm
(12)
Double-Blind Method
(11)
Genes
(11)
Pharmacology & Pharmacy
(11)
Mice
(10)
Molecular Sequence Data
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Placebo Response and Practice Effects in Schizophrenia Cognition Trials

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid

The alpha 7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Evaluation of the abuse potential of pagoclone, a partial GABAA agonist

The [alpha]7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance

Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia

The H3 antagonist ABT‐288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT‐288, in healthy young adults and elderly volunteers

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective a7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

The H 3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers: ABT-288 in subjects with schizophrenia

Exposure-Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR)

Safety, tolerability and pharmacokinetics of the histamine H 3 receptor antagonist, ABT ‐288, in healthy young adults and elderly volunteers

A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1

Suchergebnisse filtern